Edoxaban Monotherapy Triumphs in AF and Stable Coronary Disease: Insights from EPIC-CAD

Edoxaban Monotherapy Triumphs in AF and Stable Coronary Disease: Insights from EPIC-CAD The EPIC-CAD trial has provided compelling evidence that for patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), the optimal treatment strategy involves the use of anticoagulation monotherapy, specifically Edoxaban, rather than a combination therapy that includes antiplatelet agents. This […]